These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Sacituzumab tirumotecan showed “promising efficacy” regardless of PD-L1 status, said study presenter Yongmei Yin, MD, PhD.

An expert discusses the evolving role of biomarker testing in first-line metastatic triple-negative breast cancer (mTNBC), ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

An expert discusses the importance of timely biomarker testing and emerging challenges in treatment sequencing for metastatic ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...

Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan) will be paired with Merck's PD-1 inhibitor Keytruda (pembrolizumab) in a new phase 3 trial in previously ...

The move comes after Gilead has been struggling to extend the indications for its TROP2-targeting ADC Trodelvy (sacituzumab govitecan), which was the crown jewel in its $21 billion acquisition of ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.